Wall Street Zen Upgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to “Hold”

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $40.00 target price on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. Maxim Group cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Stock Performance

RVPH opened at $0.77 on Friday. The company has a fifty day moving average price of $3.15 and a two-hundred day moving average price of $7.40. Reviva Pharmaceuticals has a 52 week low of $0.59 and a 52 week high of $23.20. The firm has a market capitalization of $9.88 million, a PE ratio of -0.08 and a beta of 0.64.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. 683 Capital Management LLC bought a new position in shares of Reviva Pharmaceuticals during the second quarter worth $381,000. State Street Corp boosted its position in shares of Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after purchasing an additional 256,500 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares in the last quarter. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals in the 3rd quarter valued at $37,000. Finally, Millennium Management LLC lifted its position in Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after acquiring an additional 223,178 shares in the last quarter. 63.18% of the stock is owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.